Despite extensive research on candidate pharmacological treatments and a significant and
increasing prevalence, sepsis syndrome, and acute respiratory distress syndrome (ARDS) …

Introduction: Mesenchymal stromal (stem) cell (MSC) therapies are emerging as a promising
therapeutic intervention in patients with Acute Respiratory Distress Syndrome (ARDS) and …

Acute respiratory distress syndrome (ARDS) causes respiratory failure, which is associated
with severe inflammation and lung damage and has a high mortality and for which there is …

Sepsis and acute respiratory distress syndrome (ARDS) constitute devastating conditions
with high morbidity and mortality. Sepsis results from abnormal host immune response, with …

Acute respiratory distress syndrome (ARDS) is driven by a severe pro-inflammatory
response resulting in lung damage, impaired gas exchange and severe respiratory failure …

There is considerable interest in the potential for cell-based therapies, particularly
mesenchymal stromal cells (MSCs) and their products, as a therapy for acute respiratory …

Introduction: Despite progress in understanding the pathophysiology of the acute respiratory
distress syndrome (ARDS), it remains a devastating clinical disorder associated with high …

Mesenchymal stem/stromal cells (MSCs) offer considerable promise as a novel therapeutic
strategy for acute respiratory distress syndrome (ARDS). MSCs may be able to …

Mesenchymal stem/stromal cells (MSCs) have become the focus of intense research effort
over the past 10 years, in an effort to harness their regenerative and immune-modulating …

Acute respiratory distress syndrome (ARDS) is a multifaced disease characterized by the
acute onset of hypoxemia, worsened pulmonary compliance, and noncardiogenic …